| Clonidine Hydrochloride Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Clonidine Hydrochloride 0.1 mg | tablet | oral | 1.0 each | OTC |
| Clonidine Hydrochloride 0.2 mg | tablet | oral | 1.0 each | OTC |
| Clonidine Hydrochloride - | powder | compounding | 100.0 gram(s) | OTC |
Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for ... - PR Newswire (press release)
Addrenex has moved swiftly to develop and commercialize CloniBID, a sustained-release formulation of clonidine hydrochloride. The company recently entered ...
Wed Feb 20 14:04:16 -0500 2008
Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year ... - FOXBusiness
CloniBID and Clonicel are both a 12-hour, sustained-release formulation of clonidine hydrochloride. The patient enrollment for the Phase III trials using ...
Wed Feb 27 12:08:49 -0500 2008
Sciele Pharma, Inc. Reports Revenues and Earnings for the Second ... - Business Wire (press release)
Clonicel is a 12-hour, sustained release formulation of clonidine hydrochloride. In May 2007, the Company licensed from Plethora Solutions PSD502, ...
Wed Jul 25 13:04:53 -0400 2007
clonidine hydrochloride - The hydrochloride salt form of clonidine, an imidazoline derivate and centrally-acting alpha-adrenergic agonist as well as antagonist with antihypertensive activity. Clonidine hydrochloride binds to and stimulates central alpha2-adrenergic receptors, thereby decreasing sympathetic outflow to the heart, kidneys, and peripheral vasculature. The reduction in sympathetic outflow, leads to decreased peripheral vascular resistance, decreased blood pressure, and decreased heart rate.